The FDA has approved the first PET imaging drug in the United States for glioma, giving neuro-oncologists a tool aimed at one of the most agonizing uncertainties in brain cancer care: whether a suspicious spot on a follow-up scan is the tumor coming back or the aftermath of treatment.
Telix announced the approval of Pixclara, generically floretyrosine F 18, on Monday. The drug is indicated for use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients one month of age and older.
Roughly 24,000 new glioma cases are diagnosed in the United States each year. Gliomas account for about 30% of all brain and central nervous system tumors and about 80% of malignant ones.
An Ambiguous Scan Is One of Neuro Oncology's Hardest Problems
Radiation and chemotherapy leave marks. Weeks or months after treatment, an MRI can show a new enhancing area that looks like growing tumor but is actually inflammation and tissue injury from the therapy itself. Clinicians call this treatment-related change or pseudoprogression.
The distinction is not academic. If the finding is recurrence, a patient may need surgery, a different drug, or repeat radiation. If it is treatment effect, the right move is often to wait and rescan. Guessing wrong in either direction costs something: an unnecessary operation on the brain, or months lost while a tumor grows.
FET-PET imaging has been used for this purpose outside the United States for years and appears in international guidance, including joint recommendations from European and American nuclear medicine and neuro-oncology bodies and the National Comprehensive Cancer Network's central nervous system guidelines. Until now, no FDA-approved product existed here.
Patrick Wen, who holds the E. Antonio Chiocca Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, said an approved FET-PET product with high diagnostic accuracy would "make a significant, positive difference to the management of patients with gliomas." Kelly Sitkin, president and chief executive of the American Brain Tumor Association, said the approval would allow more precise monitoring while complementing the role of MRI, and Kevin Richardson, chief executive of Telix Precision Medicine, said it would open broad access in the United States to imaging already recognized in international guidelines.
From a Rejection Letter to an Approval
The path here was not smooth, and that history is part of the story.
In April 2025, Telix disclosed in an SEC filing on the complete response letter that the FDA had ruled the application could not be approved in its current form and that additional confirmatory clinical evidence was required. The company said no safety concerns were raised.
The two sides then negotiated a path forward. Following a Type A meeting, the company and the agency agreed on a resubmission pathway built around an additional confirmatory efficacy analysis of existing data. Telix resubmitted in March 2026, and the FDA accepted the application and set a goal date of September 11, 2026. Throughout that period, patients continued to access the agent through an FDA-approved expanded access program.
Pediatric Use Begins at One Month of Age
One of the more consequential details sits in the label. The indication covers pediatric patients from one month old, which is unusual for a cancer imaging agent and matters because gliomas are among the most common brain tumors diagnosed in children.
Safety was evaluated in 382 patients with gliomas, of whom 371 were adults and 11 were pediatric patients. Mean patient age was 57 years, with a range from 5 to 86. The company reported that the pediatric safety profile was consistent with the adult profile.
Side effects were uncommon. Headache occurred in 0.5% of patients. Nausea, injection site reaction, fatigue and malaise each occurred in fewer than 0.5%.
The drug works by targeting L-type amino acid transporters 1 and 2, which tumor cells use heavily, and labeling that targeting compound with fluorine-18 so a PET scanner can detect the signal.
Telix has also said it cleared an investigational new drug application in August for a registrational study testing the agent in brain metastases, a separate and much larger patient population. That indication is not approved, and nothing about the current label extends to cancers that have spread to the brain from elsewhere.
Scan Access, Radiation and the Limits Printed on the Label
The prescribing information contains a warning that families should hear before the appointment, not after. A negative image does not rule out recurrent or progressive glioma, and a positive image does not confirm it. Equivocal findings, including low-level or atypical uptake, can produce false positive or false negative interpretations.
That is why the indication says the scan is to be used in conjunction with other diagnostic evaluations. It is one piece of evidence to be weighed with MRI, clinical history and, when needed, tissue pathology.
The label also notes that the agent adds to a patient's long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Patients are advised to hydrate before and after administration and to void frequently afterward.
Practical access will lag the approval. PET radiopharmaceuticals are produced regionally and distributed on short timelines dictated by radioactive decay, so availability will depend on which imaging centers establish supply. Families should expect the first sites to be academic medical centers and large cancer programs in major metro areas. Insurance coverage determinations and reimbursement codes for a newly approved agent typically take months to settle, and patients should ask both the imaging center and their plan about prior authorization before scheduling.
Suspected adverse reactions can be reported to the FDA through MedWatch or by calling 1-800-FDA-1088.
Anyone with new seizures, worsening headaches, vision changes, weakness, or confusion should be evaluated urgently rather than waiting for a scheduled scan. Those symptoms need clinical attention now, whatever the imaging eventually shows.
Key Questions Answered
What did the FDA approve? Pixclara, or floretyrosine F 18, a PET imaging drug indicated to help differentiate recurrent or progressive glioma from treatment-related change in adults and children one month and older.
Why does this distinction matter? After radiation or chemotherapy, MRI can show changes that look like tumor growth but are actually treatment effect. Telling them apart determines whether a patient needs new treatment or continued monitoring.
Is this a treatment for brain cancer? No. It is a diagnostic imaging agent. It does not treat the tumor.
Can it definitively confirm recurrence? No. The label warns that a negative scan does not rule out recurrence and a positive scan does not confirm it. Results must be interpreted with other evaluations.
What are the reported side effects? In 382 patients studied, headache occurred in 0.5%. Nausea, injection site reaction, fatigue and malaise each occurred in fewer than 0.5%.
Can children receive it? Yes. The approval covers pediatric patients from one month of age, and the reported pediatric safety profile matched the adult profile.
When will it be available locally? Availability depends on regional radiopharmaceutical supply and individual imaging centers. Patients should ask their neuro-oncology team and their insurer about access and prior authorization.
